BACKGROUND: Hyperparathyroid condition might influence endothelial cells. The aim of this study was to assess flow mediated dilatation (FMD) in patients with primary hyperparathyroidism (PHPT). METHODS: We prospectively evaluated 21 patients with PHPT (9 women, 12 men; aged 50 +/- 11 years, serum calcium 11.6 +/- 0.7 mg/dl, intact parathyroid hormone (iPTH) 489 +/- 495 pg/ml) and 27 healthy control subjects (13 women, 14 men; aged 49 +/- 10 years, serum calcium 9.4 +/- 0.5 mg/dl, iPTH 28 +/- 8.5 pg/ml). Endothelial function, measured as FMD of the brachial artery using ultrasound, was calculated in two groups. To avoid confounding factors, conditions known to affect endothelial function like diabetes mellitus, hypertension, dyslipidemia, smoking, coronary and peripheral artery disease were excluded from both groups. RESULTS: FMD was lower in patients with PHPT than that in those without (10.2 +/- 5.8 vs. 19.8 +/- 5.8, P = 0.0001). FMD negatively correlated with serum calcium (r = -0.55, P = 0.002). CONCLUSION: Endothelium-dependent FMD may impair in patients with PHPT compared to controls. Endothelial dysfunction can contribute to the deleterious cardiovascular effects of PTH excess. Therapy to reduce or retard endothelial dysfunction in patients with PHPT may lead to decreased cardiovascular morbidity and mortality.
BACKGROUND: Hyperparathyroid condition might influence endothelial cells. The aim of this study was to assess flow mediated dilatation (FMD) in patients with primary hyperparathyroidism (PHPT). METHODS: We prospectively evaluated 21 patients with PHPT (9 women, 12 men; aged 50 +/- 11 years, serum calcium 11.6 +/- 0.7 mg/dl, intact parathyroid hormone (iPTH) 489 +/- 495 pg/ml) and 27 healthy control subjects (13 women, 14 men; aged 49 +/- 10 years, serum calcium 9.4 +/- 0.5 mg/dl, iPTH 28 +/- 8.5 pg/ml). Endothelial function, measured as FMD of the brachial artery using ultrasound, was calculated in two groups. To avoid confounding factors, conditions known to affect endothelial function like diabetes mellitus, hypertension, dyslipidemia, smoking, coronary and peripheral artery disease were excluded from both groups. RESULTS: FMD was lower in patients with PHPT than that in those without (10.2 +/- 5.8 vs. 19.8 +/- 5.8, P = 0.0001). FMD negatively correlated with serum calcium (r = -0.55, P = 0.002). CONCLUSION: Endothelium-dependent FMD may impair in patients with PHPT compared to controls. Endothelial dysfunction can contribute to the deleterious cardiovascular effects of PTH excess. Therapy to reduce or retard endothelial dysfunction in patients with PHPT may lead to decreased cardiovascular morbidity and mortality.
Authors: Mary C Corretti; Todd J Anderson; Emelia J Benjamin; David Celermajer; Francois Charbonneau; Mark A Creager; John Deanfield; Helmut Drexler; Marie Gerhard-Herman; David Herrington; Patrick Vallance; Joseph Vita; Robert Vogel Journal: J Am Coll Cardiol Date: 2002-01-16 Impact factor: 24.094
Authors: T Neunteufl; R Katzenschlager; A Hassan; U Klaar; S Schwarzacher; D Glogar; P Bauer; F Weidinger Journal: Atherosclerosis Date: 1997-02-28 Impact factor: 5.162
Authors: D S Celermajer; K E Sorensen; D Georgakopoulos; C Bull; O Thomas; J Robinson; J E Deanfield Journal: Circulation Date: 1993-11 Impact factor: 29.690
Authors: K E Sorensen; D S Celermajer; D Georgakopoulos; G Hatcher; D J Betteridge; J E Deanfield Journal: J Clin Invest Date: 1994-01 Impact factor: 14.808
Authors: A L Carrelli; M D Walker; M R Di Tullio; S Homma; C Zhang; D J McMahon; S J Silverberg Journal: Clin Endocrinol (Oxf) Date: 2013-02 Impact factor: 3.478
Authors: A Ekmekci; N Abaci; N Colak Ozbey; A Agayev; N Aksakal; H Oflaz; N Erginel-Unaltuna; Y Erbil Journal: J Endocrinol Invest Date: 2009-07-02 Impact factor: 4.256
Authors: M D Walker; J Fleischer; T Rundek; D J McMahon; S Homma; R Sacco; S J Silverberg Journal: J Clin Endocrinol Metab Date: 2009-09-15 Impact factor: 5.958
Authors: Cortney Bosworth; Michael C Sachs; Daniel Duprez; Andrew N Hoofnagle; Joachim H Ix; David R Jacobs; Carmen A Peralta; David S Siscovick; Bryan Kestenbaum; Ian H de Boer Journal: Clin Endocrinol (Oxf) Date: 2013-05-20 Impact factor: 3.478